Results 211 to 220 of about 4,204,588 (241)

CSL305: A Dual Functional Therapeutic Antibody Targeting Complement C2 and FcRn. [PDF]

Int J Mol Sci
Wymann S, Morales RAV, Toh WH, Remlinger J, Guse K, Ghai R, Pestel S, Sansome G, Chen CG, Rayzman V, Chia J, Quek AJ, Gorman MA, Halder P, Powers G, Ruthsatz T, Parker MW, Rowe T, Vyas S, Verhagen AM, Hardy MP.   +20 more
europepmc   +1 more source

Barium Crosslinking in Bio‐Based Sodium Alginate Films: Improved Barrier and Thermal Performance Toward Biodegradable Packaging Applications

Journal of Applied Polymer Science, EarlyView.
The graphical abstract summarizes the development and characterization of sodium alginate biodegradable films crosslinked with barium chloride (BaCl2) at concentrations of 1%, 2%, and 5% (w/v). Sodium alginate was dissolved in water, cast into films, and subsequently immersed in BaCl2 solutions to promote ionic crosslinking.
Sofia de Oliveira Pires, Cristian Berto da Silveira, Aline Fernandes de Oliveira   +2 more
wiley   +1 more source

Parallel Sequencing of the Two Arms on a Bispecific Antibody by Electron Capture Dissociation on a timsOmni Platform Reveals Several By-products in the Controlled Fab-arm Exchange Process. [PDF]

Anal Chem
Stroganova I, Ollivier S, Radić L, Smyrnakis A, Kosmopoulou M, Schinkel J, Sliepen K, Greisch JF, Heck AJR.   +8 more
europepmc   +1 more source

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

Arthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Laura Shaughnessy, Saori Shimizu, Paulette Williams, Rocío Lledó‐García, Gauri Utturkar, Baran Ufuktepe, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto, the Paediatric Rheumatology International Trials Organisation (PRINTO); the Pediatric Rheumatology Collaborative Study Group (PRCSG), Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Alberto Martini, Daniel L. Lovell, Nicolino Ruperto   +52 more
wiley   +1 more source

Nanobodies in biomedicine: from molecular characteristics to fabrication and clinical translation. [PDF]

Mil Med Res
Cao CK, Xu XY, Liang F, Yao M, Chen YY, Li XK, Su ZJ.   +6 more
europepmc   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Treatment Characteristics and Healthcare Resource Utilization Among Patients with Myasthenia Gravis Initiating Rozanolixizumab: A US Claims Database Analysis. [PDF]

Neurol Ther
Kumar M, Harrold A, Park M, Nair A, Bardenheuer K, Tarancón T, Ting A, Pata D.   +7 more
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities. [PDF]

Explor Target Antitumor Ther
Parola S, Colombo I.
europepmc   +1 more source

Fc-Binding Cyclopeptide Induces Allostery from Fc to Fab: Revealed Through in Silico Structural Analysis to Anti-Phenobarbital Antibody. [PDF]

Foods
Zhou T, Zhang H, Yu X, Pan K, Yao X, Shen X, Lei H.   +6 more
europepmc   +1 more source